



WEDNESDAY, 19th JUNE 2019 COMMENCING 10:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

- | | Enclosure |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0619 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1: Limited Submission
Rufinamide (Inovelon[®]) adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 year of age to less than 4 years of age | 2/AWMSG/0619
Appendices |
| 7. Appraisal 2: Limited Submission
Eslicarbazepine acetate (Zebinix[®]) adjunctive therapy in adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. Eslicarbazepine acetate (Zebinix [®]) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations | 3/AWMSG/0619
Appendices |
| 8. AWMSG appraisal process for medicines for rare diseases | 4/AWMSG/0619 |
| Date of next meeting – Wednesday, 17th July 2019 in Cardiff | |